Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation

International Journal of Pharmaceutics

Volumn 354, Issue 1-2, 2008, Pages 28-33

  Nakase, Ikuhiko ^a,c   Lai, Henry ^b   Singh, Narendra P ^b   Sasaki, Tomikazu ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b University of Washington   (United States)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Anticancer property; Artemisinin; Conjugation; Cytotoxicity; Transferrin

Indexed keywords

ANTINEOPLASTIC AGENT; ARTEMISININ DERIVATIVE; ARTESUNATE; CARBOHYDRATE; DIHYDROARTEMISININ; HOLOTRANSFERRIN; TRANSFERRIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CYTOTOXIC T LYMPHOCYTE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG INHIBITION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; GENE TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY;

ANIMALS; ANTINEOPLASTIC AGENTS; ARTEMISININS; DRUG DELIVERY SYSTEMS; FREE RADICALS; HUMANS; NEOPLASMS; TRANSFERRIN;

EID: 40849097597     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.09.003     Document Type: Short Survey

References (46)

1. Baker H.M., Anderson B.F., and Baker E.N. Dealing with iron: common structural principles in proteins that transport iron and heme. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 3579-3583
2. Berger T.G., Dieckmann D., Efferth T., Schultz E.S., Funk J.O., Baur A., and Schuler G. Artesunate in the treatment of metastatic uveal melanoma-first experiences. Oncol. Rep. 14 (2005) 1599-1603
3. Castañeda V.L., Parmley R.T., Saldivar V.A., and Cheah M.S. Childhood undifferentiated leukemia with early erythroid markers and c-myb duplication. Leukemia 5 (1991) 142-149
4. Chen H.H., Zhou H.J., Wu G.D., and Lou X.E. Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1. Pharmacology 71 (2004) 1-9
5. Chen H.H., Zhou H.J., Wang W.Q., and Wu G.D. Antimalarial dihydroartemisinin also inhibits angiogenesis. Cancer Chemother. Pharmacol. 53 (2004) 423-432
6. Cheng Y., Zak O., Aisen P., Harrison S.C., and Walz T. Structure of the human transferrin receptor-transferrin complex. Cell 116 (2004) 565-576
7. Creek D.J., Chiu F.C., Prankerd R.J., Charman S.A., and Charman W.N. Kinetics of iron-mediated artemisinin degradation: effect of solvent composition and iron salt. J. Pharm. Sci. 94 (2005) 1820-1829
8. Das Gupta A., Patil J., and Shah V.I. Transferrin receptor expression by blast cells in acute lymphoblastic leukemia correlates with white cell count & immunophenotype. Indian J. Med. Res. 104 (1996) 226-233
9. Dell'Eva R., Pfeffer U., Vené R., Anfosso L., Forlani A., Albini A., and Efferth T. Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate. Biochem. Pharmacol. 68 (2004) 2359-2366
10. Dhingra V., Vishweshwar Rao K., and Lakshmi Narasu M. Current status of artemisinin and its derivatives as antimalarial drugs. Life Sci. 66 (2000) 279-300
11. Efferth T., Dunstan H., Sauerbrey A., Miyachi H., and Chitambar C.R. The anti-malarial artesunate is also active against cancer. Int. J. Oncol. 18 (2001) 767-773
12. Efferth T., Benakis A., Romero M.R., Tomicic M., Rauh R., Steinbach D., Häfer R., Stamminger T., Oesch F., Kaina B., and Marschall M. Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic. Biol. Med. 37 (2004) 998-1009
13. Fritzer M., Barabas K., Szüts V., Berczi A., Szekeres T., Faulk W.P., and Goldenberg H. Cytotoxicity of a transferrin-adriamycin conjugate to anthracycline-resistant cells. Int. J. Cancer 52 (1992) 619-623
14. Fritzer M., Szekeres T., Szüts V., Jarayam H.N., and Goldenberg H. Cytotoxic effects of a doxorubicin-transferrin conjugate in multidrug-resistant KB cells. Biochem. Pharmacol. 51 (1996) 489-493
15. Gomme P.T., McCann K.B., and Bertolini J. Transferrin: structure, function and potential therapeutic actions. Drug Discov. Today 10 (2005) 267-273
16. Hamilton D.H., Turcot I., Stintzi A., and Raymond K.N. Large cooperativity in the removal of iron from transferrin at physiological temperature and chloride ion concentration. J. Biol. Inorg. Chem. 9 (2004) 936-944
17. Irie S., Kishimoto T., and Tavassoli M. Desialation of transferrin by rat liver endothelium. J. Clin. Invest. 82 (1988) 508-513
18. Kim S.J., Kim M.S., Lee J.W., Lee C.H., Yoo H., Shin S.H., Park M.J., and Lee S.H. Dihydroartemisinin enhances radiosensitivity of human glioma cells in vitro. J. Cancer Res. Clin. Oncol. 132 (2006) 129-135
19. Lai H., and Singh N.P. Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin. Cancer Lett. 91 (1995) 41-46
20. Lai H., and Singh N.P. Oral artemisinin prevents and delays the development of 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer in the rat. Cancer Lett. 231 (2006) 43-48
21. Lai H., Sasaki T., Singh N.P., and Messay A. Effects of artemisinin-tagged holotransferrin on cancer cells. Life Sci. 76 (2005) 1267-1279
22. Lai H., Sasaki T., and Singh N.P. Targeted treatment of cancer with artemisinin and artemisinin-tagged iron-carrying compounds. Expert Opin. Ther. Targets 9 (2005) 995-1007
23. Lee J.H., Engler J.A., Collawn J.F., and Moore B.A. Receptor mediated uptake of peptides that bind the human transferrin receptor. Eur. J. Biochem. 268 (2001) 2004-2012
24. Li H., and Qian Z.M. Transferrin/transferrin receptor-mediated drug delivery. Med. Res. Rev. 22 (2002) 225-250
25. Li Y., Shan F., Wu J.M., Wu G.S., Ding J., Xiao D., Yang W.Y., Atassi G., Léonce S., Caignard D.H., and Renard P. Novel antitumor artemisinin derivatives targeting G1 phase of the cell cycle. Bioorg. Med. Chem. Lett. 11 (2001) 5-8
26. Mason A.B., Miller M.K., Funk W.D., Banfield D.K., Savage K.J., Oliver R.W., Green B.N., MacGillivray R.T., and Woodworth R.C. Expression of glycosylated and nonglycosylated human transferrin in mammalian cells. Characterization of the recombinant proteins with comparison to three commercially available transferrins. Biochemistry 32 (1993) 5472-5479
27. Mercer A.E., Maggs J.L., Sun X.M., Cohen G.M., Chadwick J., O'Neill P.M., and Park B.K. Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds. J. Biol. Chem. 282 (2007) 9372-9382
28. Meshnick S.R. Artemisinin: mechanisms of action, resistance and toxicity. Int. J. Parasitol. 32 (2002) 1655-1660
29. Meshnick S.R., Tsang T.W., Lin F.B., Pan H.Z., Chang C.N., Kuypers F., Chiu D., and Lubin B. Activated oxygen mediates the antimalarial activity of qinghaosu. Prog. Clin. Biol. Res. 313 (1989) 95-104
30. Moore J.C., Lai H., Li J.R., Ren R.L., McDougall J.A., Singh N.P., and Chou C.K. Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat. Cancer Lett. 98 (1995) 83-87
31. O'Neill P.M. Medicinal chemistry: a worthy adversary for malaria. Nature 430 (2004) 838-839
32. Posner G.H., Cumming J.N., Ploypradith P., and Oh C.H. Evidence for Fe(IV) = O in the molecular mechanism of action of the trioxane antimalarial artemisinin. J. Am. Chem. Soc. 117 (1995) 5885-5886
33. Qian Z.M., Li H., Sun H., and Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev. 54 (2002) 561-587
34. Reizenstein P. Iron, free radicals and cancer. Med. Oncol. Tumor. Pharmacother. 8 (1991) 229-233
35. Rosenthal P.J., and Meshnick S.R. Hemoglobin catabolism and iron utilization by malaria parasites. Mol. Biochem. Parasitol. 83 (1996) 131-139
36. Sadava D., Phillips T., Lin C., and Kane S.E. Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells. Cancer Lett. 179 (2002) 151-156
37. Singh N.P., and Lai H. Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci. 70 (2001) 49-56
38. Singh N.P., and Lai H.C. Artemisinin induces apoptosis in human cancer cells. Anticancer Res. 24 (2004) 2277-2280
39. Singh N.P., and Panwar V.K. Case report of a pituitary macroadenoma treated with artemether. Integr. Cancer Ther. 5 (2006) 391-394
40. Singh N.P., and Verma K.B. Case report of a laryngeal squamous cell carcinoma treated with artesunate. Arch. Oncol. 10 (2002) 279-280
41. Singh M., Atwal H., and Micetich R. Transferrin directed delivery of adriamycin to human cells. Anticancer Res. 18 (1998) 1423-1427
42. Sizensky J.A., Barabas K., and Faulk W.P. Characterization of the anti-cancer activity of transferrin-adriamycin conjugates. Am. J. Reprod. Immunol. 27 (1992) 163-166
43. White N.J. Antimalarial drug resistance. J. Clin. Invest. 113 (2004) 1084-1092
44. Wiesner J., Ortmann R., Jomaa H., and Schlitzer M. New antimalarial drugs. Angew. Chem. Int. Ed. Engl. 42 (2003) 5274-5293
45. Wu W.M., Wu Y., Wu Y.L., Yao Z.J., Zhou C.M., Li Ying., and Shan F. Unified mechanistic framework for the Fe(II)-induced cleavage of qinghaosu and derivatives/analogues. The first spin-trapping evidence for the previously postulated secondary C-4 radical. J. Am. Chem. Soc. 120 (1998) 3316-3325
46. Wu G.D., Zhou H.J., and Wu X.H. Apoptosis of human umbilical vein endothelial cells induced by artesunate. Vascul. Pharmacol. 41 (2004) 205-212